FMP
TCR2 Therapeutics Inc.
TCRR
NASDAQ
Inactive Equity
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
1.48 USD
0 (0%)
About
ceo
Dr. Garry E. Menzel M.B.A., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.tcr2.comexchange
NASDAQ
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
CIK
0001750019
ISIN
US87808K1060
CUSIP
87808K106
Address
100 Binney Street
Phone
617 949 5200
Country
US
Employee
58
IPO Date
Feb 14, 2019
Key Executives
Name
Title
Pay
Year Born
Mr. Peter Olagunju
Chief Operational Officer
307.42k
1978
Mr. Richard Roomberg
Vice President of Corporation Controller
0
N/A
Dr. Alfonso Quintas Cardama M.D.
Chief Medical Officer
685.15k
1971
Dr. Angela Justice Ph.D.
Chief People Officer
0
1974
Mr. Eric M. Sullivan C.P.A.
Chief Financial Officer
0
1980
Ms. Margaret Siegel J.D.
Gen. Counsel
0
N/A
Dr. Garry E. Menzel M.B.A., Ph.D.
Pres, Chief Executive Officer & Director
923.95k
1964
Carl Mauch
Senior Director of Investor Relations & ...
0
N/A
Mr. Peter Olagunju M.B.A.
Chief Operating Officer
0
1978
Dr. Rosemary Harrison Ph.D.
Chief Bus. & Strategy Officer
522.54k
1983
Dr. Patrick A. Baeuerle Ph.D.
Founder & Member of the Advisory Board
0
1958
Mr. Eric M. Sullivan CPA
Chief Financial Officer
0
1980
As of December 31, 2024, the total employee count stands at 58, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.
